Wegovy

What is Wegovy?

Wegovy is Novo Nordisk’s semaglutide for chronic weight management. The FDA approved it in June 2021, and it is the same molecule as Ozempic, dosed higher and approved for a different job.

The important thing to know before reading anything else about it: Wegovy is not one product any more. It is a weekly injection and a daily tablet, and they are not the same treatment. Both carry the adult weight-management indication and a cardiovascular indication, but the approval for adolescents 12 and up, and the approval for a specific liver disease, belong to the injection alone. Their dose ladders are different, and if you miss a dose, the instructions run in opposite directions.

The injection comes as single-dose pens and syringes, as a FlexTouch multi-dose pen that delivers four 2.4 mg doses, and in a higher 7.2 mg strength called Wegovy HD. The tablets come in 1.5, 4, 9 and 25 mg.

Who is Wegovy approved for?

The approved indication names obesity, or overweight with at least one weight-related condition. It does not name a BMI number. The familiar thresholds of 30, or 27 with a related condition, come from the populations enrolled in the trials rather than from the indication text, which is worth knowing when an insurer quotes them back to you as an FDA rule.

The injection is additionally approved for adolescents aged 12 and up with obesity, for reducing cardiovascular events in adults with established cardiovascular disease, and, under accelerated approval, for noncirrhotic MASH with moderate to advanced (F2 to F3) fibrosis. That last one is a specific biopsy-staged liver disease, not general fatty liver, and it does not cover cirrhosis or mild fibrosis. The label also advises against taking Wegovy alongside another semaglutide product or any other GLP-1 medicine.

How much weight can you lose on Wegovy?

In the pivotal 68-week trial of the 2.4 mg injection, adults without diabetes lost about 15 percent of body weight on average, against 2.4 percent on placebo. People with type 2 diabetes lost meaningfully less on the same drug and dose, closer to 10 percent.

The newer numbers come from the label. In a 72-week trial of the higher 7.2 mg dose in adults with obesity and without diabetes, weight fell 18.8 percent, against 15.5 percent at 2.4 mg and 3.9 percent on placebo. The gain over the usual dose was 3.3 percentage points, and 45.5 percent of people on 7.2 mg lost at least a fifth of their body weight. The 25 mg tablet was studied separately over 64 weeks and produced 13.6 percent against 2.4 percent on placebo. That trial had no injection arm, so the pill and the shot have never been compared directly.

Two things the headline numbers hide. The higher dose is not simply better: the label still names 2.4 mg as the usual maintenance dose, and discontinuation for side effects ran higher on 7.2 mg than on placebo. And no trial figure is the drug on its own. Every arm in these programs received structured lifestyle support, and the drug effect was measured on top of it. Results varied widely between individuals in every arm.

Beyond weight, the injection was tested in a large cardiovascular outcomes trial in people with established cardiovascular disease and obesity or overweight. Major cardiovascular events fell by about a fifth. Cardiovascular death on its own was not significantly reduced, and the trial does not support a heart-failure or overall-mortality claim.

In adolescents 12 and up, the trial measured percent change in BMI rather than percent weight loss, because BMI in a growing teenager is not the same measure as adult body weight. BMI fell 16.1 percent against a small increase on placebo.

How does Wegovy work?

Semaglutide acts on the receptor for GLP-1, a hormone your gut releases when you eat. Your own GLP-1 is broken down within a minute or two, while semaglutide is engineered to last around a week, which is what makes weekly injection possible.

The weight loss comes mainly from eating less. The drug acts on the parts of the brain that handle hunger and food reward, so appetite falls and the constant background pull toward food quiets down. It is not a change in how much energy you burn.

It also slows how quickly the stomach empties, which adds to fullness and is where most of the nausea comes from. That effect tends to fade as your body adjusts, and plenty of people lose weight without ever feeling sick.

The tablet is the same molecule, but its daily schedule is not a half-life story. Oral semaglutide is absorbed poorly and variably through the gut, so the limiting factor is getting the drug in rather than how long it lasts. That is why the fasting instructions are part of the dose rather than a suggestion.

Wegovy pill: the daily oral tablet

The tablet is a genuinely different product from the pen, and the differences are practical.

It climbs on its own schedule: 1.5 mg daily for 30 days, then 4 mg, then 9 mg, reaching a maintenance dose of 25 mg once daily from day 91. It has to be taken on an empty stomach in the morning, with no more than 4 ounces of water and nothing else to drink, swallowed whole, and followed by at least 30 minutes before eating, drinking or taking other oral medicines.

The tablets carry the adult weight-management and cardiovascular indications. They are not approved for adolescents and not approved for MASH, and their safety has not been established in either group. If someone cannot tolerate the 25 mg tablet, the label suggests considering the 1.7 mg weekly injection instead.

One trap worth naming: three different oral semaglutide products now exist, at three different dose scales. Wegovy tablets go to 25 mg, Rybelsus to 14 mg, and Ozempic tablets to 9 mg. Milligrams are not comparable between them, and the label says so outright.

What are the side effects of Wegovy?

Mostly digestive, mostly early, and mostly temporary. They cluster around dose increases and ease over time. Each rate below is from the placebo-controlled trials of the 2.4 mg injection, shown against the placebo rate in the same trials, because the raw figure alone overstates what the drug adds. Headache is the clearest example: 14 percent sounds like a lot until you see the 10 percent on placebo.

The serious warnings are worth knowing and mostly uncommon. Pancreatitis is a labeled precaution rather than an established risk. Gallbladder disease is an uncommon but real class effect. Because the drug slows stomach emptying, the label instructs patients to tell their care team before any procedure requiring general anesthesia or deep sedation, and states that the available data do not yet support a specific instruction about pausing the drug beforehand. There is also a small increase in resting heart rate.

The suicidality warning that drove headlines in 2023 and 2024 was removed from the Wegovy label in February 2026, after FDA reviewed the question and did not find that these drugs increase suicidal thinking or behavior. Wegovy was one of only three products that ever carried it. What remains is ordinary vigilance rather than a drug-specific warning: if you notice new or worsening depression or mood changes, contact your prescriber.

Practical management, which rests on clinical experience rather than trials of the advice itself: smaller meals, less fatty food and alcohol around injection day, and enough fluid. Persistent severe abdominal pain is not a symptom to wait out.

Who should not take Wegovy?

The label lists exactly two contraindications. Several other conditions are not stop signs but are worth raising with your prescriber first.

The boxed warning drives the first: because semaglutide caused thyroid C-cell tumors in rodents, anyone with a personal or family history of medullary thyroid cancer, or with MEN 2, should not take it. The second is a known hypersensitivity to semaglutide or any ingredient.

Wegovy dosage: schedule and strengths

The injection starts at 0.25 mg once weekly and steps up every four weeks, reaching the usual maintenance dose of 2.4 mg at week 17.

Two points most coverage misses. 1.7 mg is a real maintenance dose, not just a rung on the way up: for adults the label names either 1.7 mg or 2.4 mg, with 2.4 mg recommended. And the maintenance dose is indication-specific, listed separately for weight reduction, cardiovascular risk reduction, adolescents, and MASH.

The 7.2 mg dose (Wegovy HD) is an option, not a destination. It is for adults on the weight indication who have tolerated 2.4 mg for at least four weeks and need more, and it carries its own adverse-reaction profile.

Missed doses are where the two forms diverge most sharply, so check which one you are on:

• Injection: if the next scheduled dose is more than 2 days (48 hours) away, take the missed dose as soon as possible. If it is less than 2 days away, skip it.
• Tablets: skip the missed dose entirely and take the next one the following day.

How do you use the Wegovy pen?

Wegovy injection comes in more than one device, and they do not operate identically. The steps below are a summary. Follow the Instructions for Use that came with your exact presentation, and ask your pharmacist or prescriber to walk you through it the first time.

1. Check the medicine and the device as your Instructions for Use direct.
2. Inject under the skin of the abdomen, thigh, or upper arm. On Wegovy all three are permitted for self-injection, which is not true of every GLP-1.
3. Use a different spot within that area each time. The label instructs rotation and gives no reason for it.
4. Inject once a week, on the same day each week. The time of day and the site can change without changing the dose.
5. Dispose of needles in a sharps container, and never share a pen with another person even with a new needle.

Storage depends on the presentation, and the windows genuinely differ. Single-dose pens and syringes are refrigerated, and may be kept at 46 to 86°F for up to 28 days before the cap is removed. The FlexTouch multi-dose pen is refrigerated before first use and can then be kept for 56 days at 59 to 86°F or refrigerated. Tablets are stored at room temperature in their original bottle, away from moisture.

How much does Wegovy cost?

List price is not what most people pay, and the self-pay ladder now depends on which form and dose you are on. The figures below move often, so confirm them before acting.

Coverage for obesity treatment is a patchwork. Roughly a third of the largest employers cover it, far fewer state Medicaid programs do, and where coverage exists it often carries prior authorization, BMI rules, step therapy, or a requirement to join a lifestyle program.

Medicare deserves its own note, because the rule has a trap in it. A temporary GLP-1 Bridge runs from 1 July 2026 through the end of 2027 at $50 a month for people who meet its criteria, and it covers weight-management prescriptions only. If the same drug is prescribed to reduce cardiovascular risk, that is a Part D-coverable indication and disqualifies the prescription from the Bridge. It is the indication on the prescription that decides, not simply your diagnosis.

Savings cards can bring costs down for people with commercial insurance, but they exclude anyone on Medicare, Medicaid, VA or TRICARE coverage.

Wegovy vs Zepbound, Ozempic, and Mounjaro

Wegovy vs Zepbound

The one place a direct comparison exists. In a 72-week head-to-head, tirzepatide produced 20.2 percent weight loss against semaglutide’s 13.7 percent, with more people reaching a 25 percent loss. It was an open-label trial funded by Eli Lilly, and it compared each drug at its maximum tolerated dose. The asymmetry that rarely gets mentioned runs the other way: Wegovy carries a cardiovascular outcomes indication and Zepbound does not, though Zepbound is approved for obstructive sleep apnea. Compare every GLP-1 →

Wegovy vs Ozempic

Same molecule, different products. Ozempic is approved for type 2 diabetes and, in people who also qualify, for cardiovascular and kidney risk reduction. It tops out at 2 mg. Wegovy is dosed higher and approved for weight management. Compare every GLP-1 →

Wegovy vs Mounjaro

Mounjaro is tirzepatide, which acts on two receptors (GIP and GLP-1) rather than one, and it is approved for type 2 diabetes rather than weight management. Comparisons between them on weight are indirect, since the direct trial was against Zepbound. Compare every GLP-1 →

Looking beyond the brand? See every Wegovy alternative →

How to get Wegovy

Wegovy is prescription-only, and a licensed provider has to write it. Sites offering it without a prescription are not selling the approved product. Three legitimate paths:

Wegovy myths and misconceptions

Five claims we hear constantly, and what is actually true.

• Myth Wegovy and Ozempic are different drugs.

  They are the same molecule, semaglutide, from the same maker. Wegovy is dosed higher and approved for weight management; Ozempic is approved for type 2 diabetes. Same drug, different products, and not interchangeable.

• Myth Wegovy is a cosmetic or vanity drug.

  It is approved to treat obesity, and separately to reduce major cardiovascular events in adults with established cardiovascular disease. It also carries an accelerated approval for a specific liver disease, noncirrhotic MASH with F2 to F3 fibrosis.

• Myth You can stop once you hit your goal weight.

  In the withdrawal trials, groups that stopped and started nothing else regained much of the lost weight over about a year. It is treated as a long-term therapy rather than a course you finish.

• Myth The Wegovy pill and the Wegovy shot are the same treatment.

  They share a molecule and two indications, but not all of them. The pediatric and MASH indications belong to the injection only. The ladders differ, and if you miss a dose the injection may tell you to catch up while the tablets tell you to skip it.

• Myth Compounded semaglutide is the same as Wegovy.

  Compounded versions are not FDA-approved products, and their dose and purity are not reviewed the way an approved product's are.